Viewing Study NCT00072969


Ignite Creation Date: 2025-12-24 @ 10:54 PM
Ignite Modification Date: 2025-12-25 @ 8:22 PM
Study NCT ID: NCT00072969
Status: COMPLETED
Last Update Posted: 2008-03-04
First Post: 2003-11-12
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module References Module